

3 November 2025

Mathew Regan Commences as Group Chief Executive Officer

Driving next-generation innovation in RRAM, robotics, and AI-enabled sensor technologies and drive global expansion

Key Highlights:

- Mathew Regan has officially commenced as Group Chief Executive Officer, effective 1 November 2025.
- Former CEO of Artrya Limited (ASX: AYA), where he successfully reshaped the company's point of care AI-driven clinical platform and secured FDA clearances.
- Brings extensive multi-disciplinary expertise spanning digital health, AI, advanced manufacturing, and technology commercialisation, with a track record in scaling emerging technologies into global platforms.
- Mr Regan's appointment comes at a pivotal time for dorsaVi as the Company advances towards commercialising next-generation RRAM powered AI, Sensors and Robotics Technologies.

Melbourne, Australia, 3 November 2025: dorsaVi (ASX:DVL) (dorsaVi or the Company) is pleased to announce that Mathew Regan has commenced in his role as Group Chief Executive Officer, effective 1 November 2025.

As previously announced (ASX Announcement 28 August 2025) on Mr Regan joins dorsaVi with a proven track record in transforming emerging technologies into globally scalable platforms. His prior leadership roles include CEO of Artrya Limited (ASX: AYA) and senior executive positions at Imdex (ASX: IMD), equipping him with extensive experience in scaling innovation across the digital health, artificial intelligence, and advanced manufacturing sectors.

In his most recent role at Artrya, Mr Regan successfully repositioned the company's AI driven clinical imaging platform, secured FDA clearances and enabled adoption by hospitals and clinicians globally. Widely recognised for his ability to translate vision into delivery, Mr Regan

brings broad experience across digital health, artificial intelligence, advanced manufacturing, and IT infrastructure.

Driving the Next Phase of Growth

Mr Regan's appointment comes at a pivotal time for dorsaVi as the Company advances the commercialisation of its next-generation RRAM-enabled sensor architecture and explores broader applications through its Reflex platform¹. These innovations underpin dorsaVi's strategy to expand beyond traditional clinical and workplace monitoring into high-growth verticals such as robotics, neuromorphic computing, and edge AI.

With internal testing already demonstrating breakthrough reductions in latency and power consumption for biomedical sensing applications², dorsaVi is well-positioned to leverage RRAM-enabled capabilities across multiple industries. The ongoing evaluation of the Reflex platform for next-generation robotics and human–machine interfaces mark a significant step toward enabling sub-millisecond reactions and in-sensor decision-making for autonomous systems, collaborative robots, and advanced wearables.

In parallel, the recent launch of Artemis Labs³, dorsaVi's dedicated innovation subsidiary, provides a unified platform to accelerate the development of RRAM-enabled sensor systems, edge AI models, and robotic reflex applications. Artemis Labs consolidates dorsaVi's core IP with its exclusive RRAM license and will act as the Company's engine for developing next-generation human–machine interface technologies.

Mr Regan's track record in scaling emerging technologies into global platforms makes him uniquely positioned to accelerate these initiatives, secure strategic partnerships, and unlock new commercial opportunities in both existing and adjacent markets.

Gernot Abl, Chairman of dorsaVi, said:

"We are delighted to officially welcome Mat as he commences as Group CEO. His leadership marks an exciting new chapter for dorsaVi. With deep experience in scaling technology-driven businesses, Mat is ideally positioned to accelerate our expansion into high-growth markets such as robotics and edge AI."

Andrew Ronchi will continue as CEO of dorsaVi's sensor division, focusing on:

- Scaling adoption of the Company's FDA-cleared movement analytics platform
- o Driving U.S. commercial growth and strategic partnerships
- Supporting integration of next-generation RRAM-enabled capabilities

He will step down from his role as a director of the Company to dedicate his efforts to leading the division's operational and commercial strategy.

_

¹ Refer to ASX announcement dated 04 August 2025

² Refer to ASX announcement dated 22 July 2025

³ Refer to ASX announcement dated 20 August 2025

Change of Registered Office Address

In accordance with ASX Listing Rule 3.14, dorsaVi (ASX: DVL) (dorsaVi or the Company) advises that, effective immediately, the Company's registered office address has changed to Level 50/108 St Georges Terrace, Perth WA 6000. The Company's principal place of business and other contact details remain unchanged.

This release has been authorised for lodgement by the Company's Board of Directors.

- ENDS -

For further information about dorsaVi, please contact:

Gernot Abl Chairman +61 419 802 653 Email: ga@dorsaVi.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- Workplace: dorsaVi enables employers to assess risk of injury for employees as well as
 test the effectiveness of proposed changes to OHS workplace design, equipment or
 methods based on objective evidence. dorsaVi works either directly with major
 corporations, or through an insurance company's customer base with the aim of
 reducing workplace compensation and claims. dorsaVi has been used by major
 corporations including London Underground, Vinci Construction, Crown Resorts,
 Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral
 Resources and BHP Billiton.
- Clinical: dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com